Veterans Affairs San Diego Healthcare System, San Diego, California, USA.
Department of Anesthesiology, University of California, San Diego, San Diego, California, USA.
FASEB J. 2019 Jan;33(1):1209-1225. doi: 10.1096/fj.201800876R. Epub 2018 Aug 31.
Statins, which reduce LDL-cholesterol by inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are among the most widely prescribed drugs. Skeletal myopathy is a known statin-induced adverse effect associated with mitochondrial changes. We hypothesized that similar effects would occur in cardiac myocytes in a lipophilicity-dependent manner between 2 common statins: atorvastatin (lipophilic) and pravastatin (hydrophilic). Neonatal cardiac ventricular myocytes were treated with atorvastatin and pravastatin for 48 h. Both statins induced endoplasmic reticular (ER) stress, but only atorvastatin inhibited ERK1/2, Akt, and mammalian target of rapamycin signaling; reduced protein abundance of caveolin-1, dystrophin, epidermal growth factor receptor, and insulin receptor-β; decreased Ras homolog gene family member A activation; and induced apoptosis. In cardiomyocyte-equivalent HL-1 cells, atorvastatin, but not pravastatin, reduced mitochondrial oxygen consumption. When male mice underwent atorvastatin and pravastatin administration per os for up to 7 mo, only long-term atorvastatin, but not pravastatin, induced elevated serum creatine kinase; swollen, misaligned, size-variable, and disconnected cardiac mitochondria; alteration of ER structure; repression of mitochondria- and endoplasmic reticulum-related genes; and a 21% increase in mortality in cardiac-specific vinculin-knockout mice during the first 2 months of administration. To our knowledge, we are the first to demonstrate in vivo that long-term atorvastatin administration alters cardiac ultrastructure, a finding with important clinical implications.-Godoy, J. C., Niesman, I. R., Busija, A. R., Kassan, A., Schilling, J. M., Schwarz, A., Alvarez, E. A., Dalton, N. D., Drummond, J. C., Roth, D. M., Kararigas, G., Patel, H. H., Zemljic-Harpf, A. E. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes.
他汀类药物通过抑制 3-羟基-3-甲基戊二酰辅酶 A 还原酶来降低 LDL-胆固醇,是最广泛使用的药物之一。骨骼肌病是一种已知的他汀类药物诱导的不良反应,与线粒体变化有关。我们假设,在两种常见的他汀类药物(阿托伐他汀(亲脂性)和普伐他汀(亲水性))之间,以脂溶性依赖性方式,类似的作用也会发生在心肌细胞中。用阿托伐他汀和普伐他汀处理新生的心室心肌细胞 48 小时。两种他汀类药物都诱导内质网(ER)应激,但只有阿托伐他汀抑制 ERK1/2、Akt 和哺乳动物雷帕霉素靶蛋白信号;减少 caveolin-1、营养不良蛋白、表皮生长因子受体和胰岛素受体-β的蛋白丰度;降低 Ras 同源基因家族成员 A 的激活;并诱导细胞凋亡。在心肌细胞等效 HL-1 细胞中,阿托伐他汀而不是普伐他汀降低线粒体耗氧量。当雄性小鼠口服给予阿托伐他汀和普伐他汀长达 7 个月时,只有长期的阿托伐他汀而不是普伐他汀诱导血清肌酸激酶升高;心脏线粒体肿胀、排列不齐、大小不一和断开;内质网结构改变;抑制与线粒体和内质网相关的基因;以及在给药的前 2 个月,心脏特异性 vinculin 敲除小鼠的死亡率增加 21%。据我们所知,我们是第一个在体内证明长期阿托伐他汀给药改变心脏超微结构的人,这一发现具有重要的临床意义。-戈多伊,J.C.,Niesman,I.R.,布西娅,A.R.,卡桑,A.,席林,J.M.,施瓦茨,A.,阿尔瓦雷斯,E.A.,道尔顿,N.D.,德拉蒙德,J.C.,罗斯,D.M.,卡拉里加斯,G.,帕特尔,H.H.,泽姆利奇-哈普夫,A.E.阿托伐他汀,但不是普伐他汀,抑制心肌细胞中的 Akt/mTOR 信号并扰乱线粒体超微结构。